Search
for

    Sort by

    Research 661–690 of 1000+

    1. Cancer Chemotherapy: an Introduction 1989 · 4 citations
    2. Alopecia Areata and malignancies: uncertainties clarified by a large-scale population-based study Archives of Dermatological Research · 2024 · 3 citations
    3. Cell Surface B2m-Free Human Leukocyte Antigen (HLA) Monomers and Dimers: Are They Neo-HLA Class and Proto-HLA? Biomolecules · 2023 · 3 citations
    4. Immunohistochemical, pharmacovigilance, and omics analyses reveal the involvement of ATP-sensitive K+ channel subunits in cancers: role in drug–disease interactions Frontiers in Pharmacology · 2023 · 3 citations
    5. The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review International Journal of Impotence Research · 2022 · 3 citations
    6. Beeinflussen Medikamente gegen das benigne Prostatasyndrom Stimmung oder Kognition? Der Urologe · 2019 · 3 citations
    7. Synthesis and structural characterization of a new dinuclear platinum(III) complex, [Pt<sub>2</sub>Cl<sub>4</sub>(NH<sub>3</sub>)<sub>2</sub>{μ-HN=C(O)Bu<sup>t</sup>}<sub>2</sub>] 2022 · 2 citations
    8. Case Report: Disorder of Sexual Development in a Chinese Crested Dog With XX/XY Leukocyte Chimerism and Mixed Cell Testicular Tumors Frontiers in Veterinary Science · 2022 · 2 citations
    9. A study of clinical and investigational profile of hirsute women at a tertiary care center in Western India Clinical Dermatology Review · 2020 · 2 citations
    10. Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men Current Geriatrics Reports · 2019 · 2 citations
    11. Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg Neurology Neuroimmunology & Neuroinflammation · 2019 · 2 citations
    12. Pseudoglucagonoma syndrome secondary to pancreatitis: A case report Journal of Dr. YSR University of Health Sciences. · 2015 · 2 citations
    13. Icariside II inhibits gastric cancer progression by suppressing the Wnt/β-catenin signaling pathway Cytotechnology · 2025 · 1 citations
    14. Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese Human Genomics · 2024 · 1 citations
    15. Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride Journal of personalized medicine · 2023 · 1 citations
    16. Are ABO/Rh blood groups A risk factor for polycystic ovary syndrome? Medicine · 2023 · 1 citations
    17. The Multiple Consequences of Obesity IntechOpen eBooks · 2022 · 1 citations
    18. 46, XY 5-Alpha Reductase Deficiency in a 36-Year-Old Phenotypic Female Patient AACE clinical case reports · 2022 · 1 citations
    19. Review of Topical Therapies for Beard Enhancement Indian Journal of Pharmaceutical Sciences · 2020 · 1 citations
    20. Bilateral nevus comedonicus of the eyelids: An unusual cause of ptosis and ectropion American journal of ophthalmology. Case reports · 2019 · 1 citations
    21. A randomized double blind controlled study evaluating efficacy & Safety of vatika enriched coconut hair oil on hair health in women with hair fall and dandruff 2017 · 1 citations
    22. Editorial Comment Urology · 2013 · 1 citations
    23. Finasterid in der Behandlung der benignen Prostatahyperplasie Der Urologe · 2012 · 1 citations
    24. Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor Daehan namseong gwahag hoeji · 2012 · 1 citations
    25. Basic research in biostimulation 1987 · 1 citations
    26. Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance Pharmaceuticals · 2026
    27. ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability Zenodo (CERN European Organization for Nuclear Research) · 2026
    28. ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability Zenodo (CERN European Organization for Nuclear Research) · 2026
    29. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS) The Aging Male · 2026
    30. Case Report: Pulsed electric field treatment of metastatic liver disease demonstrating a possible abscopal response Frontiers in Immunology · 2026